Erlotinib,an epidermal growth factor receptor tyrosine kinase inhibitor

Zhiqiang TangChinese 2005

Abstract

Erlotinib(Tarceva~(D○R)) is an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor used in molecular targeted therapy.It is one of a new group of drugs that targets tiny flaws in the cell's communication machinery.By inhibition of phosphorylation of tyrosine kinase,erlotinib blocks the EGFR tyrosine kinase protein in the cancer cell from getting a message that tells the cell to grow and divide.Clinical studies demonstrated that this small molecular agent has antitumor activities.US FDA approved erlotinib tablets for treatment of locally advanced or metastatic Non Small-Cell Lung Cancer(NSCLC) after failure of at least one prior chemotherapy regimen in 2004.
BibTeX
@inproceedings{tang2005erlotinib,
  author = {Zhiqiang Tang},
  title = {{Erlotinib,an epidermal growth factor receptor tyrosine kinase inhibitor}},
  booktitle = {Chinese},
  year = {2005},
}

Loading related content...

Figure